Who Discovered BPC-157? Predrag Sikirić

Who discovered BPC-157? Predrag Sikirić and colleagues at the University of Zagreb did the foundational work. Their 1992 paper described a partly characterized peptide in human stomach fluid called BPC. In 1993, the same group described BPC-157, a 15-amino-acid fragment they had characterized and investigated.

That distinction matters. The team reported isolating the parent BPC material from gastric juice; BPC-157 was the smaller sequence researchers synthesized. So "comes from the stomach" is useful shorthand, but it isn't a literal description of the material in today's vial.

Who discovered BPC-157?

Science rarely gives one person a clean discovery moment. Sikirić is the name most closely attached to BPC-157, but the original papers list a Zagreb team that included Marijan Petek, Rudolf Rucman, Sven Seiwerth, Zdenko Grabarević and others. Sikirić was the first-listed author, and the affiliation was the Medical Faculty at the University of Zagreb in Croatia.

Their starting question wasn't sports recovery. They were studying how the stomach responds to stress and injury. The idea was cytoprotection, meaning protection of cells from damage, and whether a protective response beginning in the stomach might reach other organs.

The earliest PubMed-indexed paper in this trail is the team's 1992 Acta Physiologica Hungarica report. It called BPC a newly, partly characterized gastric-juice peptide and discussed experiments centered on stomach protection.

A year later, the team's 1993 Journal of Physiology-Paris paper said a much larger BPC peptide had recently been isolated from gastric juice. It then described BPC-157 as a fully characterized 15-amino-acid fragment thought to carry an important part of the larger material's activity. That 1993 paper is the clearest first publication of BPC-157 itself.

What does BPC stand for?

BPC stands for Body Protection Compound. It was a research name for the Zagreb group's broad protection hypothesis, not proof that the fragment protects every part of a human body.

The "157" is a historical identifier. The early indexed papers use it but do not explain what the number counts. It is not the peptide's length: BPC-157 is a pentadecapeptide, simply a peptide made of 15 amino acids. It is also not a dose or its molecular weight.

This is a good place to slow down. The confident-sounding name came before large human trials. A name can tell you where an idea started; it cannot tell you whether that idea held up in people.

Why a stomach peptide was studied in tendons and vessels

The leap started inside the original hypothesis. If BPC represented a general response to injury rather than only an anti-ulcer signal, the researchers had a reason to test the fragment in other tissues. That is how the literature moved from the gut into tendons, muscle and blood vessels.

In a 2003 Journal of Orthopaedic Research study, investigators cut rat Achilles tendons and also studied tendon cells outside the body. They reported differences in tissue and mechanical measurements after BPC-157 exposure. These were rat and laboratory findings, not evidence that a human tendon will respond the same way.

A later Journal of Molecular Medicine study examined angiogenesis, the growth of new blood vessels. It found changes in blood-flow recovery and vessel number in rats, along with signaling changes in human blood-vessel cells studied in a dish. Again, that explains the research direction. It does not turn a cell or rat result into a human outcome.

That musculoskeletal branch is also why BPC-157 is now discussed alongside TB-500. Wolverine is a compounded blend of those two peptides, but combining two research ideas does not create human trial evidence for the blend.

When did people enter the BPC-157 story?

The early human chapter is frustratingly incomplete. FDA's 2026 evidence review identified several small studies, including older rectal studies in healthy volunteers and people with ulcerative colitis, but much of that work survives as sparse summaries or meeting abstracts rather than full modern trial reports. The complete inventory belongs in Promise's BPC-157 human studies guide.

The clearest published systemic-safety paper arrived in 2025, and it included only two people. In that intravenous pilot, a 58-year-old man and a 68-year-old woman, both previously exposed to intravenous BPC-157, received 10 mg and then 20 mg on consecutive days. The investigators reported no side effects or meaningful changes in the biomarkers they checked during the short observation.

That can tell us what happened to two previously exposed people over a few days. It cannot estimate common or rare risks, long-term safety, or whether BPC-157 helps an injury. The authors called for future studies. No large randomized trial has followed in the published record, and the public documents do not establish one reason why.

How BPC-157 reached the gray market

There was no single documented launch from the Zagreb lab into today's online market. Instead, two tracks developed. The formal literature remained mostly animal and laboratory work, while online fitness communities and sellers recast those findings as recovery claims.

A peer-reviewed study of mainstream e-commerce listings sampled Amazon UK, eBay UK and Alibaba in June 2020. BPC-157 was among the peptides the researchers found. They described a gray market: products sold outside the usual prescription and pharmacy controls, sometimes with labeling that did not establish quality or true origin.

That route made the peptide easy to encounter without making the evidence stronger. It also separated the buyer from a clinician, a dispensing pharmacy and a traceable patient record. The modern Wolverine name belongs to this later recovery conversation, not to the 1992 or 1993 discovery papers.

Where BPC-157 stands today

As of September 9, 2026, the day this article was written, BPC-157 is not FDA-approved. FDA's April 22 update removed BPC-157 from Category 2 after both nominators withdrew, and the agency's current safety-risk page lists it among substances nominated but withdrawn. FDA then reviewed the free-base and acetate forms on its own initiative. At the July 23 advisory meeting, the panel voted 8–6–1 to recommend both forms for possible inclusion on the 503A Bulks List, the list of raw ingredients traditional compounding pharmacies may use under federal conditions. The vote was nonbinding, not a drug approval or a final rule.

Promise's FDA peptide decision explainer covers the full meeting, while why BPC-157 is not FDA-approved follows the BPC-specific paper trail. The useful point here is smaller: the regulatory history did not rewrite the discovery history, and the vote did not supply the human trials that are still missing.

A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. The compounded formulation offered through Promise is not FDA-approved. A prescription route does provide something a gray-market sale cannot: a named reviewing provider, a patient-specific prescription, a licensed U.S. compounding pharmacy and a record for follow-up.

At Promise, a licensed provider reviews every request and not everyone qualifies.